With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
IEX — frequently asked questions
Is IDEX Corporation overvalued?
In our latest published analysis dated 2026-10-11, IEX looks meaningfully overvalued. The price recorded at analysis is USD 234 versus our fair value of USD 168; the high endpoint is presented separately as potential value of USD 185. That implies roughly 28.1% downside to fair value at that date.
Our latest published report, analyzed 2026-10-11, gives IEX a fair value of USD 168 and a potential value of USD 185. The conclusion is triangulated across multiple valuation models and weighted by reliability for IDEX Corporation's archetype; it is a dated research output, not a live price.
Should I buy IEX now?
Our latest published rating for IEX, analyzed 2026-10-11, is Sell. IDEX Corporation looks meaningfully overvalued at the analysis-date price of USD 234 versus fair value of USD 168; potential value is USD 185. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for IEX?
The dedicated bear-case section in our report analyzed 2026-10-11 documents IDEX Corporation's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is IEX's rating?
Our latest published rating for IEX, analyzed 2026-10-11, is Sell, with a published moat assessment of 7.5/10 (Narrow). It reflects our fair value of USD 168, the potential value of USD 185, and the price recorded at analysis (USD 234).
Accelerated commercial adoption of proprietary precision fluidic cooling manifolds in hyperscale AI data centers combined with non-idling high-purity water heating systems for advanced semiconductor fabs, driving Health and Science Technologies organic growth into double digits.
Main risk
Expiration of tariff refunds accompanied by selective customer rebate concessions and persistent input inflation.
IDEX Corporation is assigned a Sell rating as its share price of $234.29 on October 9, 2026 trades at a substantial 39.14% premium to the house Fair value of $168.38. While IDEX maintains exceptional operational execution and secular momentum in Health and Science Technologies, prevailing valuation multiples leave no safety margin against persistent European and Asian industrial headwinds.4,5,8
IDEX demonstrates admirable commercial discipline across its precision fluidics and instrumentation portfolio. In the second quarter of 2026, management raised full-year organic revenue growthguidance to 5%-6% and adjusted diluted EPS guidance to $8.70-$8.85, supported by low double-digit expansion in Health and Science Technologies where data center liquid cooling and semiconductor equipment customers are prebooking capacity through 2027. Operating margins are projected to expand from 20.23% in FY2025 toward 23.2% by FY2030 as 80/20 operational rigor optimizes acquired business units.5,7
However, this operational strength is heavily discounted by market pricing. IDEX trades at 23.98x forward earnings, commanding a premium over diversified peer ITW (21.40x forward P/E) despite ITW generating significantly higher operating margins (26.90% vs IDEX's 20.23%). Furthermore, international operations remain exposed to cyclical destocking across Europe ($846.2M revenue) and Asia ($563.0M revenue), while guided FY2026 capex surges to $110M. With the house Fair value synthesized at $168.38, representing an implied return of -28.13%, capital preservation mandates a Sell rating.3,4,5,7,8
Switching Costs
Custom-engineered fluidic sub-assemblies, precision micro-pumps, and specialized valves are designed directly into customer instruments and machines, creating prohibitive platform re-engineering, regulatory validation, and operational switching costs for OEMs.5
Proprietary patents and specialized trade secrets protect key technologies, such as non-idling high-purity water heating systems for semiconductor manufacturing and specialized automation fluidics.5
Cycle upside
During an industrial upcycle, semiconductor fabrication equipment builds surge alongside hyper-scale AI data center construction, driving rapid order conversion for IDEX's precision liquid cooling manifolds and high-purity fluidic assemblies. Concurrently, general industrial demand in North America and Europe rebounds, filling rapid-replenishment channels and driving operating margin expansion through overhead absorption and 80/20 operational efficiencies.5
House recommendation
The investment committee maintains a Sell rating on IDEX Corporation. The shares price in flawless multi-year execution across secular niches while ignoring cyclical exposure in European and Asian industrial markets. Investors should eliminate or trim equity exposure, as the share price of $234.29 on October 9, 2026 implies -28.13% downside to the house Fair value of $168.38.4
Company overview
IDEX Corporation is an applied solutions manufacturer specializing in fluidics systems, precision optics, fire and rescue equipment, and metering devices. The company serves global niche industrial, life sciences, semiconductor, and municipal markets through three operating segments: Health and Science Technologies, Fluid and Metering Technologies, and Fire and Safety Diversified Products.
IDEX generates broad geographic revenue diversification, with the United States accounting for $1,760.8M (50.9%), Europe generating $846.2M (24.5%), and Asia contributing $563.0M (16.3%) of total FY2025 revenue ($3,457.5M). The business maintains low customer concentration, with its largest individual customer representing less than 3% of net sales.
In a severe macroeconomic stress scenario, synchronized industrial contractions in Europe and Asia cascade into broad-based original equipment manufacturer inventory destocking across the Fluid and Metering Technologies and Fire and Safety Diversified Products segments. As international revenues contract, domestic general industrial customers reduce rapid-replenishment order velocity. Compounding top-line deceleration, the cessation of tariff refund recoveries coincides with selective pricing rebate pressure, causing gross margins to compress below 42% and driving consolidated operating margins under 19.5%. Concurrently, full-year capital expenditures of $110M committed to prebooked capacity must still be funded against declining operating cash flows, reducing annual free cash flow below $450M and leaving debt of $1.89B elevated. In this environment, IDEX's compounder valuation premium evaporates, compressing its forward multiple toward 17.0x and exposing existing equity holdings to severe capital loss.
IDEX Corporation possesses a durable narrow economic moat anchored primarily by high switching costs and specialized intangible assets. In its Health and Science Technologies segment, IDEX manufactures mission-critical fluidic sub-assemblies that are embedded directly into life science analytical instruments, medical diagnostic devices, and semiconductor wafer fabrication equipment. Because the cost of component failure is catastrophic while the unit cost represents a fraction of the total tool value, OEMs face substantial re-certification risks and operational delays if they attempt to switch component suppliers.
The company enhances this architectural defensibility through proprietary process intellectual property and continuous co-development with leading OEMs. For example, IDEX's patented high-purity water heating solution for semiconductor manufacturing operates without continuous idling, delivering vital water and energy conservation benefits that competitive offerings cannot replicate. Combined with disciplined 80/20 operational execution that prunes product line complexity and focuses resources on core accounts, IDEX sustains gross margins of 44.51% and maintains return on capital above its cost of financing.
The highlighted cell is Fair value when every assumption sits at its base level ($168.38). Each row and column shows what Fair value becomes when one assumption moves.
Upgrade the rating; Evaluate order backlog duration into subsequent fiscal periods and monitor whether customer prebooking extends beyond initial commitments before adjusting portfolio weightings.
A decisive beat driven by accelerating Health and Science Technologies demand and faster margin accretion would demonstrate that high-margin platforms can outpace European industrial drag, narrowing the gap to Fair value.
In-line
Maintain Sell; Maintain disciplined risk limits and review position allocation against diversified industrial peers that offer wider margins of safety.
Trigger: Results delivering within guided full-year organic revenue growth and adjusted diluted ranges while track sequential pacing
Broader industrial sector benchmark metrics demonstrate disciplined capital allocation, with an industry capex-to-revenue ratio of 4.1% and capex-to-depreciation of 0.68 as of 2026-10-05. IDEX historically operated below this benchmark with FY2025 capex of $63.6M (1.84% of revenue), but is expanding its investment phase with FY2026 capex guided to ~$110M (~3.0% of revenue) to build capacity for prebooked OEM backlog.5,7
Bull cycle
During an industrial upcycle, semiconductor fabrication equipment builds surge alongside hyper-scale AI data center construction, driving rapid order conversion for IDEX's precision liquid cooling manifolds and high-purity fluidic assemblies. Concurrently, general industrial demand in North America and Europe rebounds, filling rapid-replenishment channels and driving operating margin expansion through overhead absorption and 80/20 operational efficiencies.
§11 Position management
Sizing
0%
With the stock trading at $234.29 against a Fair value midpoint of $168.38, the shares carry a -28.13% implied return. A 0% portfolio allocation is recommended for fundamental equity accounts to prevent capital impairment.4
Risk
Risk management mandates disciplined avoidance of equity purchases under prevailing valuation multiples. Investors holding legacy positions should utilize trailing stop orders and sell call options against long inventory to hedge downside risk. Portfolio managers should closely monitor quarterly operating margin prints across the Fluid and Metering Technologies segment to detect early signs of pricing lag or tariff rebate friction, liquidating remaining holdings if consolidated operating margins breach 20.0%.
§12 Investor perspectives
Fundamental Value Investor
Avoid
Trading at 23.98x forward earnings and a 39.14% premium to Fair value ($168.38), IDEX offers no margin of safety against macroeconomic deceleration or multiple contraction.4
Quality Compounder Growth Investor
Avoid
Although IDEX demonstrates strong 80/20 execution and secular growth in Health and Science Technologies, organic compounding is over-discounted by the market, limiting upside even under the bull case ($185.31).5
Cyclical / Income Investor
Avoid
With a modest baseline dividend yield and international revenue (Europe $846.2M, Asia $563.0M) vulnerable to manufacturing contraction, cyclical risk outweighs cash returns.
§14 Final recommendation
Action
Sell
IDEX Corporation is assigned a Sell rating. While IDEX is a high-grade industrial business benefiting from narrow-moat switching costs in mission-critical fluidics, the market price of $234.29 trades at an excessive 39.14% premium to the house Fair value of $168.38, implying -28.13% return.4
At 23.98x forward earnings, IDEX trades well above diversified peer ITW (21.40x forward P/E) despite trailing ITW in operating profitability (20.23% vs 26.90%). Current pricing leaves zero buffer for cyclical headwinds in Europe ($846.2M revenue) or Asia ($563.0M revenue).
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-11 · Published 2026-10-11 · Provider-adjusted · cited for 4 figuresCited in Scenarios
Under the bear case, European and Asian industrial stagnation deepens, triggering distributor destocking and OEM order deferrals across FMT and FSDP segments. Operating margins contract as tariff rebate expirations and persistent input cost inflation outpace commercial price increases, while elevated FY2026 capex of $110M dampens free cash flow generation.
Ways this thesis can break
Tariff rebate expiration and commercial pricing lag trigger sustained operating margin contraction across FMT and HST segments.
Management noted selective rebate activity on tariff adjustments in Q2 and tough margin comparisons as tariff pricing took effect faster than underlying costs. If tariff refunds cease and input inflation persists without offsetting OEM price increases, consolidated operating margin falls below 19.5%, down from FY2025 20.23%.5,7
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Protracted European and Asian industrial recession induces OEM order cancellation and destocking across FMT and FSDP.
Europe contributed $846.2M (24.5%) and Asia $563.0M (16.3%) of FY2025 revenue ($3,457.5M). Ongoing geopolitical tensions, rate headwinds, and industrial caution could drive international orders negative, reducing top-line growth by over 500 bps relative to guided 5%-6%.5,7,8
FV impact
-0.9%
Revenue and EPS growth 5 points lower for five years
IDEX trades at 23.98x forward earnings, relying on a terminal exit multiple of 21.0x. High-quality diversified peer ITW trades at 21.40x forward P/E while delivering 26.90% operating margins, and peer OTIS trades at 14.57x. If IDEX's growth normalizes without closing the margin gap, its multiple derates 20% toward 17.0x-18.0x.3,4
FV impact
-3.1%
Terminal multiple 20% lower
Trigger
Within 24 months
Simultaneous industrial capex contraction, capacity under-absorption, and elevated capex burden.
FY2025 FCF was $616.8M on capex of $63.6M. Guided FY2026 capex surges to $110M. If OEM demand drops and operating cash flow falls 25% from $680.4M to ~$510M while capex remains at $110M, FCF collapses below $450M.5,6,7
FV impact
-1.6%
The analyst's bear scenario path and multiple as the base case
Trigger
Early-warning signals to monitor
The five developments that would weaken our investment case.
OEM customers delay capital equipment deployments or push out delivery dates for semiconductor and life science tools, slowing high-margin volume recovery.
Current:Low double-digit FY2026 target
Alert if< 4.0%
IDEX delivers a return on invested capital of 9.52%, which exceeds its moderate weighted average cost of capital of 8.71%, generating a positive economic profit spread of 81 basis points. However, this return profile lags premier peer ITW, which generates a 26.90% operating margin and return on equity exceeding 100%.2,3
7.5/ 10
Narrow
Sources of advantage
01Switching Costs — Custom-engineered fluidic sub-assemblies, precision micro-pumps, and specialized valves are designed directly into customer instruments and machines, creating prohibitive platform re-engineering, regulatory validation, and operational switching costs for OEMs.Wide
02Intangible Assets — Proprietary patents and specialized trade secrets protect key technologies, such as non-idling high-purity water heating systems for semiconductor manufacturing and specialized automation fluidics.Moderate
Operating margin expands from 20.23% in FY2025 to 21.5% in FY2026 and reaches 23.2% by FY2030.5,7
Share repurchases retire ~0.7% to 1.0% of diluted shares annually, funded by steady operating cash flows.5
Terminal exit P/E multiple of 21.0x, aligning with mature high-grade peer ITW (21.40x).3
Under the base case, IDEX achieves organic revenue growth accelerating into 5%-6% in FY2026, consistent with raised management guidance, followed by 5.99% in FY2027. Operating margin expands from 20.23% in FY2025 toward 23.2% by FY2030 through disciplined 80/20 operational execution. Diluted EPS increases from $6.41 in FY2025 to $8.83 in FY2026 and $9.63 in FY2027. At an exit P/E of 21.0x, in line with mature peer ITW (21.40x), intrinsic value aligns with the house Fair value midpoint of $168.38.1,3,5,7
Under the bull case, rapid commercial adoption of liquid cooling manifolds in hyperscale AI data centers and surging semiconductor fab tool installations accelerate organic revenue growth above 8% annually. Operating margins expand toward 25.0%, approaching specialized peers Nordson (27.40%) and ITW (26.90%), lifting potential intrinsic value toward $185.31.3,5
Meeting guidance confirms the operational baseline but leaves the current market valuation stretched above $168.38, offering insufficient margin of safety given cyclical risks.
Miss
Maintain Sell; Immediately scrutinize segment order books and reassess exposure given the absence of operational buffers to absorb negative revisions.
Trigger: Consolidated organic revenue growth or operating margin falling below the guided band due to international industrial destocking or pricing concessions
An earnings miss caused by distributor inventory adjustments in Europe or selective pricing rebates would accelerate valuation multiple compression toward historical peer averages.
Earnings quality is supported by healthy operating cash flow conversion and disciplined working capital control. Reported net income translates reliably into free cash generation, with capital expenditures focused primarily on prebooked OEM capacity expansions. Operating margins are driven by structural gross profitability rather than non-operating items, although selective tariff rebate concessions introduce minor timing variability in reported segment profitability.
Estimate momentum
Consensus earnings per share and revenue estimates experienced upward revisions following second-quarter earnings, supported by management raising full-year outlook across organic revenue growth, operating margin, and adjusted diluted earnings per share. Analysts increased forward projections to reflect accelerating backlog delivery in Health and Science Technologies, while maintaining moderate expectations for international industrial recovery.
IDEX exhibits strong cash flow conversion underpinned by gross margins of 44.51%. In FY2025, operating cash flow reached $680.4M and free cash flow totaled $616.8M, delivering free cash flow conversion of 127.6% relative to net income of $483.2M. While FY2026 free cash flow will temporarily moderate due to the $110M capex ramp, the underlying asset-light manufacturing profile ensures normalized free cash flow will exceed $650M annually as new capacity scales.5,6,7
IDEX exercises a disciplined capital allocation strategy that balances internal capacity reinvestment, bolt-on acquisitions, and shareholder returns. For FY2026, growth capital expenditures are targeted at ~$110M, stepping up from $63.6M in FY2025 to support prebooked data center programs. The company maintains a steady share repurchase pace of ~$75M quarterly (~$300M annualized) through the remainder of 2026, which systematically reduces the diluted share count by approximately 0.7% to 1.0% annually against 75.3M shares outstanding. Total company debt of $1.89B is supported by $680.4M in operating cash flow, maintaining an equity weight of 90.16% in the capital structure.
IDEX generates an attractive return on capital, with its ROIC of 9.52% exceeding its moderate WACC of 8.71%. The trajectory is supported by the systematic deployment of 80/20 operational initiatives across acquired businesses, lifting operating margins from 20.23% in FY2025 toward 23.2% by FY2030. However, ROIC expansion is tempered by elevated goodwill and intangible asset balances from prior acquisitions.
ROIC exceeds WACC by 81 basis points (9.52% vs 8.71%), demonstrating value creation, although the spread is modest compared to peers such as ITW (operating margin 26.90%) and Nordson (operating margin 27.40%).
FY2025 gross profit of $1,538.8M on revenue of $3,457.5M represents a 44.51% gross margin, compared to the broader industrial peer average of 37.5%.
Premium pricing power provides an operating cushion that protects consolidated gross profitability against selective tariff rebates and material inflation.
Capex surge reflects high-return growth capacity expansion rather than structural maintenance drag.
Capexguidance was increased from $63.6M in FY2025 to ~$110M in FY2026.
Near-term free cash flow is dampened by approximately $46M, but targeted capacity de-bottlenecks prebooked OEM order conversion through 2027.
Europe generated $846.2M (24.5%) and Asia generated $563.0M (16.3%) of FY2025 revenue.
Macroeconomic stagnation in foreign manufacturing centers creates an ongoing drag on organic top-line compounding that offsets domestic life-science acceleration.
Income statement breakdownHow business scale converts into reported profit.Jun 30, 2026
StockMarketAgent.AI
Revenue$920.6MCost of revenue−$493.8MGross profit$426.8MOperating expenses−$226.9MOperating income$199.9MNon-operating items and tax−$56.5MNet income$143.4M
Financial history data
Revenue
$920,600,000
Cost of revenue
$493,800,000
Gross profit
$426,800,000
Operating expenses
$226,900,000
Operating income
$199,900,000
Non-operating items and tax
-$56,500,000
Net income
$143,400,000
Balance sheet snapshotHow reported assets are held and financed at the selected period.
StockMarketAgent.AI
Assets held asFinanced by
Total assets$6.9BCash$580MCurrent assets$1.6BTotal liabilities$2.9BCurrent liabilities$575.4MShareholders’ equity$4B
Balance sheet breakdown data
Total assets
$6,927,000,000
Cash
$580,000,000
Current assets
$1,643,200,000
Total liabilities
$2,900,800,000
Current liabilities
$575,400,000
Shareholders’ equity
$4,026,200,000
Cash-flow statement breakdownHow cash moved through operating, investing, and financing activities in FY2025.
StockMarketAgent.AI
Operating cash reconciliation
Net income$483.2MDepreciation and amortization+$206.5MStock-based compensation+$27.3MOther operating adjustments−$36.6MOperating cash flow$680.4M
IDEX Corporation (IEX) trades at 24.0x forward earnings against a peer median of 23.3x. Its EV/EBITDA of 19.0x compares with a peer median of 19.2x. The comparison uses 4 peers: Otis Worldwide Corporation, Nordson Corporation, Rockwell Automation Inc. and Illinois Tool Works Inc., as of 2026-10-11.
Bear cycle
In a cyclical downturn, prolonged industrial weakness in Europe and Asia exacerbates customer destocking across general industrial and municipal markets. Lower factory utilization leads OEM partners to cancel or defer blanket purchase commitments, resulting in fixed cost de-leverage across FMT and FSDP manufacturing facilities. Margin compression is intensified if input cost inflation persists while tariff rebates expire.
Secular trends
Trend
Impact
Note
Data Center Liquid Cooling Adoption
positive
Accelerating power density in artificial intelligence data center infrastructure requires advanced liquid cooling solutions, fueling strong multi-year demand for specialized precision pneumatic manifolds and valves.
Advanced Semiconductor Fab Capacity Expansions
positive
Next-generation sub-2nm semiconductor fabrication requires extreme chemical purity and ultra-precise thermal control, increasing adoption of IDEX's patented non-idling high-purity water heating solutions.
European Industrial Production Softness
negative
Persistent macroeconomic stagnation, high interest rates, and regulatory friction across European industrial centers dampen general factory automation and industrial equipment demand.
Positioning
IDEX is strategically positioned as a premier precision component supplier, insulating itself from broader cyclical volatility through high niche diversification and mission-critical OEM integration. Its broad product line across Health and Science Technologies ($1,490.7M), Fluid and Metering Technologies ($1,222.5M), and Fire and Safety Diversified Products ($744.3M), paired with a customer base where no client exceeds 3% of sales, enables IDEX to outperform commoditized industrial machinery peers during mid-cycle transitions.8
Entry tranches
Level
Action
Why
$168.38 (House Fair Value Midpoint)
Re-evaluate fundamental risk-reward profile for potential rating upgrade.
At the house Fair value midpoint, share price reflects full compensation for European industrial destocking and tariff rebate friction.
Consider initiating long coverage review if operational checkpoints hold.
The low end of the synthesized valuation range provides an adequate margin of safety against cyclical de-rating.
Exit tranches
Level
Action
$234.29 (Current Analysis Price)
Liquidate existing positions or initiate structured reduction of legacy holdings.
$243.80 (52-Week High)
Complete final position liquidation before valuation multiple mean reversion.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
